This is the summary at the start of the (33 page) report:Targeting the leading cause of vision loss. OPT is a clinical-stagebiotech focused on eye disease. The company is evaluatingOPT-302, a drug for the treatment of Age-related MacularDegeneration (AMD) and Diabetic Macular Edema (DME); marketsworth >US$10bn in 2018. In Aug-2019, OPT reported positive PhaseIIB data in AMD, and we expect progression into Phase III in 2H20.
OPT.AX 12m Price Target: A$4.90 Price: A$2.70 Upside: 81.5%
OPT-302 has multi-billion dollar potential. As successful ascurrent treatments have been, they only inhibit up to two of thefactors responsible for the disease (VEGF-A/B). Over half of patientsdo not achieve significant vision gains, and a quarter experiencecontinued vision loss. OPT-302 is intended for use in combinationwith these treatments, blocking a further two factors (VEGF-C/D),hence targeting improved outcomes via a more complete blockade.We forecast non-risk-adjusted peak sales of US$5.0bn (US$2.0bnrisk-adjusted), of which US$3.4bn relates to wAMD (US$1.7bn).
Several stages of upside ahead of binary Phase III data.Risk-adjusting for development and commercial hurdles implies aTarget Price of A$4.9 (market cap: US$760m). With several drugs inlate-stage development, and existing patents expiring from 2020-23,we see several motivated partner candidates who could view OPTas low-cost optionality on lifecycle management and/or marketexpansion for multi-billion dollar opthalmology franchises. Webelieve a licensing agreement is the likely path tocommercialisation, and we estimate a global deal could add A$1.2 toOPT shares (+45%). OPT expects Phase IIA data for DME in early2020, for which a positive outcome could add A$0.6 (+22%). IfOPT-302 is ultimately approved for both wAMD and DME in US andRoW, we estimate a further A$5 of upside to A$11 (+320% upside).
We initiate with a Buy rating (add to Conviction List).
- Forums
- ASX - By Stock
- price target
This is the summary at the start of the (33 page) report:OPT.AX...
-
- There are more pages in this discussion • 58 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $403.8M |
Open | High | Low | Value | Volume |
36.5¢ | 38.5¢ | 36.0¢ | $606.6K | 1.610M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 75584 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.5¢ | 33006 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 75584 | 0.370 |
4 | 82716 | 0.365 |
5 | 170618 | 0.360 |
3 | 224103 | 0.355 |
10 | 228990 | 0.350 |
Price($) | Vol. | No. |
---|---|---|
0.375 | 33006 | 1 |
0.380 | 8766 | 1 |
0.385 | 8766 | 1 |
0.390 | 15594 | 5 |
0.395 | 63850 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |